Back to Basics: Prioritizing Communication as a Key Instrument in Managing Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) have come to experience a tremendous increase in therapeutic options with disease-modifying antirheumatic drugs (DMARDs).1 After decades of dissatisfying drug therapy results with conventional synthetic DMARDs (csDMARDs) only, the introduction of the first tumor necrosis factor inhibitors in the late 1990s has revolutionized RA treatment.2 Over the last 3 decades, different biologic DMARDs (bDMARDs) and...